Assignee
IGM BIOSCIENCES INC
US·21 granted patents·32 pending applications·198 citations·filing 2013–2023
Top patents by PatentIndex Score
53 records- 0198US10975147B2Modified J-chainIGM BIOSCIENCES INC·Filed 2020·Granted Apr 13, 2021·8 cites·28 claims
- 0298US10400038B2Modified J-chainIGM BIOSCIENCES INC·Filed 2015·Granted Sep 3, 2019·21 cites·21 claims
- 0398US9951134B2Modified J-chainIGM BIOSCIENCES INC·Filed 2017·Granted Apr 24, 2018·25 cites·23 claims
- 0497US11542342B2Binding molecules with modified J-chainIGM BIOSCIENCES INC·Filed 2020·Granted Jan 3, 2023·4 cites·27 claims
- 0597US11192941B2Multi-valent human immunodeficiency virus antigen binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2020·Granted Dec 7, 2021·4 cites·20 claims
- 0697US10618978B2Binding molecules with modified J-chainIGM BIOSCIENCES INC·Filed 2016·Granted Apr 14, 2020·16 cites·7 claims
- 0796US10954302B2Anti-PD-L1 antibodiesIGM BIOSCIENCES INC·Filed 2017·Granted Mar 23, 2021·10 cites·19 claims
- 0896US10899835B2IgM Fc and J-chain mutations that affect IgM serum half-lifeIGM BIOSCIENCES INC·Filed 2020·Granted Jan 26, 2021·7 cites·28 claims
- 0994US10787520B2Multimeric bispecific binding molecules specific for CD20 and CD3IGM BIOSCIENCES INC·Filed 2016·Granted Sep 29, 2020·13 cites·31 claims
- 1093US10604559B2Multi-valent hepatitis B virus antigen binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2016·Granted Mar 31, 2020·15 cites·18 claims
- 1193US9458241B2Antibody induced cell membrane woundingIGM BIOSCIENCES INC·Filed 2013·Granted Oct 4, 2016·21 cites·20 claims
- 1291US10689449B2Multimeric death domain-containing receptor-5 (DR5) antibodies and uses thereofIGM BIOSCIENCES INC·Filed 2016·Granted Jun 23, 2020·12 cites·30 claims
- 1391US10351631B2Constant chain modified bispecific, penta- and hexavalent Ig-M antibodiesIGM BIOSCIENCES INC·Filed 2014·Granted Jul 16, 2019·18 cites·22 claims
- 1490US11535664B2Multi-valent hepatitis B virus antigen binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2020·Granted Dec 27, 2022·2 cites·19 claims
- 1590US11401337B2Modified human IgM constant regions for modulation of complement-dependent cytolysis effector functionIGM BIOSCIENCES INC·Filed 2018·Granted Aug 2, 2022·6 cites·36 claims
- 1689US10570191B2Multi-valent human immunodeficiency virus antigen binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2016·Granted Feb 25, 2020·7 cites·14 claims
- 1788US11639389B2Binding molecules with modified J-chainIGM BIOSCIENCES INC·Filed 2016·Granted May 2, 2023·4 cites·14 claims
- 1888US11555075B2Modified J-chainIGM BIOSCIENCES INC·Filed 2018·Granted Jan 17, 2023·2 cites·46 claims
- 1983US11578131B2Polynucleotides encoding death domain-containing receptor-5 (DR5) binding moleculesIGM BIOSCIENCES INC·Filed 2020·Granted Feb 14, 2023·1 cites·23 claims
- 2081US12486336B2Binding molecules with modified J-chainIGM BIOSCIENCES INC·Filed 2022·Granted Dec 2, 2025·0 cites·13 claims
- 2181US2023279111A1Modified j-chainIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2280US2024002514A1Anti-pd-l1 antibodiesIGM BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2379US10822399B2IgA multi-specific binding moleculesIGM BIOSCIENCES INC·Filed 2015·Granted Nov 3, 2020·2 cites·17 claims
- 2479US2024124584A1Igm fc and j-chain mutations that affect igm serum half-lifeIGM BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2578US2023203173A1Tumor necrosis factor (tnf) superfamily receptor igm antibodies and uses thereofIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2669US2022403009A1Multimeric coronavirus binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 2768US2026070999A1Methods of treating autoimmune disorders using multimeric anti-cd38/anti-cd3 antibodiesIGM BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 2868US2021163600A1Anti-pd-l1 antibodiesIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 2967US2022340676A1Modified human igm constant regions for modulation of complement-dependent cytolysis effector functionIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3067US2022177595A1Multimeric gitr binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3166US2021087273A1IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFEIGM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3266US2022169751A1Multimeric ox40 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3364US2023058162A1Multimeric coronavirus binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3464US2022106399A1Multimeric cd40 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3563US2025051473A1Anti-cd38 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2023·Application pending·0 cites
- 3663US2021388098A1Multimeric cd137/4-1bb binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 3760US2024076392A1Anti-cd123 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2022·Application pending·0 cites
- 3859US2021032357A1Cd20 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 3955US2024002526A1Uses of effector cell engaging molecules with moieties of differing potenciesIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 4054US2022372142A1Multimeric antibodies with enhanced selectivity for cells with high target densityIGM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4154US2022289856A1Multimeric bispecific anti-cd123 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4253US2023073926A1Highly sialylated multimeric binding moleculesIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 4352US2022106398A1Anti-gitr antigen-binding domains and uses thereofIGM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4452US2022306760A1Igm glycovariantsIGM BIOSCIENCES INC·Filed 2020·Application pending·0 cites
- 4551US2023174660A1Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancerIGM BIOSCIENCES INC·Filed 2021·Application pending·0 cites
- 4651US2019338040A1Multimeric cd137/4-1bb binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2017·Application pending·0 cites
- 4751US2019338041A1Multimeric cd40 binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2017·Application pending·0 cites
- 4851US2019330360A1Multimeric gitr binding molecules and uses thereofIGM BIOSCIENCES INC·Filed 2017·Application pending·0 cites
- 4950US2021380701A1MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULESIGM BIOSCIENCES INC·Filed 2019·Application pending·0 cites
- 5050US2020392239A1Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancerIGM BIOSCIENCES INC·Filed 2019·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when IGM BIOSCIENCES INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →